Stephen Liu, Chief, Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Phase II ETOP 18-21 AMAZE-lung trial of 2L amivantamab + lazertinib + bevacizumab after 3G TKI in EGFR NSCLC The Lancet Respiratory Medicine. RR 39%. TRAEs included infusion reaction 58%, rash 50%, VTE 17% which would likely be mitigated with SQ and modern support.”
Title: Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial
Authors: Ross A Soo, Sanjay Popat, Urania Dafni, Adrianus Johannes de Langen, Ernest Nadal, Patricia Iranzo, Martin Früh, Maurice Pérol, Giulio Metro, Maria Angeles Sala, Marc Cucurull Salamero, Ferdinando Cerciello, Alfredo Addeo, Manuel Dómine, Youssef Oulkhouir, Nicolas Cloarec, Rafael López Castro, Patrizia Froesch, Heidi Roschitzki-Voser, Barbara Ruepp, Adriana Gasca-Ruchti, Tereza Dellaporta, Solange Peters, Rolf A Stahel
You can also read:
AMAZE-lung Trial: Triple Targeting With Amivantamab, Lazertinib and Bevacizumab in EGFR-Mutant NSCLC
